On April 7, Rigerna announced the completion of the first closing of its Pre-A financing round. The funds raised in this initial stage wereGolden Ease Renewaland other investments. This market-based financing will be used to rapidly advance the clinical research of the core product RG002C0106, as well as the continued development of liver-targeted delivery technology and the drug pipeline. This follows the company's over 100-million-yuan angel+ round completed last year.After financing, new financing was obtained.。
Rigerna was founded in 2022 and focuses on the research and development as well as industrialization of small nucleic acid drugs. The companyFirst Pipeline RG002C0106It is an siRNA drug developed targeting the complement factor C3.Intended for the treatment of primary or secondary glomerular diseases mediated by complement. This product has demonstrated excellent efficacy and safety in preclinical studies, and is currently undergoing Phase 1 clinical trials, with Phase 2 clinical trials soon to be initiated.
In addition, RigernaDelivery technologies have been established for various extrahepatic tissues, including the kidneys, skeletal muscles, adipose tissue, heart, central nervous system, lungs, eyes, and more. Drug pipelines targeting the liver and extrahepatic tissues have been developed, with preclinical and clinical research advancing through multiple modalities.
In order to allow everyone to learn and communicate with each other better,WeChat Official Account "Cell Gene Therapy" TeamA WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。Article Recommendation (Click on the article title below to open the original):
A Cell Therapy Company in China Completes Pre-A Round Financing
Emerging Player in China’s Large Molecule Drug Delivery Field Completes Angel+ Round of Financing Worth Tens of Millions of Yuan
Chinese Team Publishes in Cell, Reveals Optimal Timing for Stem Cell Infusion, New Strategy to Prevent aGVHD
A Gene Drug Company in China Completes New Round of Financing
$500 Million! WuXi Biologics Completes a Deal
China's First Solid Tumor Cell Drug Marketing Application Accepted
Total Investment of 120 Million Yuan! Suzhou Rigerna Therapeutics, a Biotech Company Focused on Cell Therapy and Gene Technology Translation, Opens in China
Another "Dark Horse" Emerges in the Field of Immune Cell Therapy: How to Break Through the Industrial Technology Threshold?
China's National Health Commission Releases New Regulations on Human Genetic Resources Management: Biological Samples Containing Minimal Residual or Free Cells or Genes, Such as Serum and Plasma, No Longer Fall Under the Scope of Human Genetic Resource Materials Management
Total investment of 2.5 billion yuan, construction area of 220,000 square meters, focusing on cell and gene therapy, a leading cell and gene industry transformation base in China officially inaugurated.
From the Latest Report of People's Daily: How Cell Therapy is Reshaping the Future of Medicine
Investment of no less than 200 million yuan, the first cell industrial production base in Hainan lands
An RNA Drug Approved for Marketing
Disclaimer: The content is sourced from the company's official channels and Medicilon., this articleAim to share knowledge, all content is for reference only and does not constitute any advice.
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)